• Ashley EA, McGready R, Hutagalung R et al. (2005) A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin–piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clinical Infectious Diseases 41, 425432 (Epub 15 July 2005).
  • Myint HY, Tipmanee P, Nosten F et al. (2004) A systematic overview of published antimalarial drug trials. Transactions of the Royal Society of Tropical Medicine and Hygiene 98, 7381 (Review).
  • Nosten F, Ter Kuile F, Chongsuphajaisiddhi T et al. (1991) Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 337, 11401143.
  • Nosten F, Luxemburger C, Ter Kuile F et al. (1994) Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate–mefloquine combination. Journal of Infectious Diseases 170, 971977.
  • Nosten F, McGready R, Ashley E & White NJ (2005) Malaria misconceptions. Lancet 365, 653.
  • Simpson JA, Watkins ER, Price RN et al. (2000) Mefloquine pharmacokinetic–pharmacodynamic models: implications for dosing and resistance.. Antimicrobial Agents and Chemotherapy 44, 34143424.
  • Tangpukdee N, Krudsood S, Thanachartwet W et al. (2005) An open randomized clinical trial of Artekin vs. artesunate–mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health 36, 10851091.
  • Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A & Wongsrichanalai C (2006) In vivo sensitivity monitoring of mefloquine monotherapy and artesunate–mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Tropical Medicine and International Health 11, 211219.
  • WHO (2006) WHO Guidelines for the Treatment of Malaria. (WHO/HTM/MAL 2006.1108) World Health Organization, Geneva, Switzerland.